Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial

Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial

Background Prostate cancer (PCa) has been under investigation as a target for antigen-specific immunotherapies in metastatic disease settings for the last two decades leading to a licensure of the first therapeutic cancer vaccine, Sipuleucel-T, in 2010. However, neither Sipuleucel-T nor other experi...

Full description

Bibliographic Details
Main Authors: Andrew Protheroe, Pedro J Romero, Richard Bryant, Lucy Carter, Julianne Hollidge, Ian Poulton, Megan Baker, Celia Mitton, Andrea Baines, Armin Meier, Richard Harrop, Ruth MacPherson, Steven Kennish, Susan Morgan, Selena Vigano, James Catto, Adrian V S Hill
Format: Article
Language:English
Published: BMJ Publishing Group 2020-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/1/e000928.full

Internet

https://jitc.bmj.com/content/8/1/e000928.full

Similar Items